US › Healthcare

Rocket Pharmaceuticals Inc (RCKT)

US · Healthcare · Biotechnology

$3.50+0.57%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$123.2M

EPS

$-0.15

EPS estimate

$0.28

EPS came in at -0.15 against a street estimate of 0.28 — a miss of 153.6%.

Key statistics

Market cap

$382.0M

Forward P/E

0.0

P/B

1.02

Book value

$3.37

EPS (TTM)

$-0.17

52-week high

$5.45

52-week low

$2.53

50-day MA

$3.55

200-day MA

$3.59

Beta

0.50

Analyst view

Analysts rate Rocket Pharmaceuticals Inc a strong buy (17 buy, 1 hold, 0 sell out of 18) with an average price target of $8.84.

Shareholding

Insiders

3.24%

Institutions

91.70%

Largest institutional holders

Fund	Stake
RTW INVESTMENTS, LLC	16.11%
BlackRock Inc	7.14%
Citigroup Inc	4.65%
Vanguard Portfolio Management, LLC	4.27%
State Street Corp	4.09%
Millennium Management LLC	3.64%
Vanguard Capital Management, LLC	3.44%
Maverick Capital Ltd	3.25%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rocket Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.